

1. Vote on appointing the company's external auditor from among the nominated candidates based on the recommendation of the Audit Committee to examine, review, and audit the consolidated financial statements for the first quarter of the fiscal year 2026, and to determine their fees.
2. Vote on the Board of Directors' recommendation to approve the Employee Share Program (Long-Term Incentive Plan) for the group's employees, and to authorize the Board to manage the plan, link its mechanism to performance, and make the necessary amendments as needed. (Attached)
3. Voting on the Board of Directors' resolution to appoint (Dr. Zeyad Othman Al-Hekail) as an Independent Member of the Board of Directors, effective from his appointment date on November 4, 2025, to complete the current Board term until its expiry on December 31, 2027, replacing the former Non-Executive Member, (Mr. Noor Al-Rahman Abid.) (Curriculum Vitae attached).
4. Voting on delegating the Board of Directors with the powers of the Ordinary General Assembly to grant the license referred to in paragraph (1) of Article Twenty-Seven of the Companies Law, for a period of one year from the date of approval by the General Assembly or until the end of the term of the authorized Board of Directors, whichever comes first, in accordance with the conditions set forth in the Implementing Regulations of the Companies Law for Listed Joint Stock Companies.
5. Voting on the business and contracts to be entered into between Dr. Soliman Abdul Kader Fakeeh Hospital Company ("DSFH Jeddah") and Soliman Abdul Kader Fakeeh Real Estate Company, in which the Chairman of the Board, Mr. Ammar Soliman Abdul Kader Fakeeh, the Vice Chair of the Board, Dr. Manal Soliman Abdul Kader Fakeeh, and Board Member Dr. Mazen Soliman Abdul Kader Fakeeh have an indirect interest. The transaction relates to the acquisition of a majority stake (50.01%) in Diagnostic Elite Company Ltd. for a total amount of SAR 70,000,000.

Persons whose votes will be excluded on this item: Soliman Abdul Kader Fakeeh Real Estate Company, Dr. Mazen Soliman Fakeeh, Mr. Ammar Soliman Fakeeh, Dr. Manal Soliman Fakeeh.

The Audit Committee reviewed the transaction and its key documents with executive management, including its strategic rationale, structure and total consideration of SAR 70 million (SAR 55.35 million payable to Fakeeh Real Estate Company and SAR 14.65 million to be injected as a capital contribution into Diagnostic Elite). The Committee confirmed that the total consideration of SAR 70 million lies below the indicative fair value range of SAR 114–125 million for the 50.01% stake, and that the SAR 55.35 million cash consideration is equivalent to Fakeeh Real Estate Company's investment cost in Diagnostic Elite. Accordingly, the Audit Committee concluded that the transaction, in its current structure and terms, does not include any preferential terms in favor of the related party.

Shareholders may review the Audit Committee's recommendation on the transaction, Diagnostic Elite's audited financial statements for the last two financial years, and the valuation report via the following link: ([https://liqaa.wamid.sa/agm\\_page/fakeeh-care-group-20251221](https://liqaa.wamid.sa/agm_page/fakeeh-care-group-20251221)) starting from 01:00AM on Saturday 11/09/1447H corresponding to 28/02/2026G until the end of the Assembly Meeting's time.